Enzymatic activity of Src family kinases and the recruitment of adaptor proteins to the GPVI/FcRγ-chain complex have to be tightly regulated to limit thrombus growth and to prevent inappropriate intravascular platelet activation, but the underlying mechanisms are only partially understood. It has been shown that lack of the immunoreceptor tyrosine-based inhibitory motif-bearing receptors, such as platelet endothelial cell adhesion molecule-1, 15 carcinoembryonic antigen cell adhesion molecule-1, 16 or the T-cell ubiquitin ligand-2 phosphatase TULA-2, 17 results in a selective platelet hyperreactivity to GPVI agonists, which is based on hyperphosphorylation of Src-family kinases and phospholipase C (PLC) γ2 and leads to a prothrombotic phenotype in vivo.
The PDZ and LIM domain (PDLIM) protein family comprises 7 members (PDLIM1-7) sharing similar domain structures 18 and biological functions in mammalian cells. 19 They are composed of 1 or 2 PDZ domains at the N-terminus, a short linker region, and 1 or 3 LIM domains at the C-terminus. [20] [21] [22] The PDLIM protein family contains muscle-specific and ubiquitously expressed proteins that associate with actin cytoskeletal proteins (β-tropomyosin, α-actinin) 23, 24 and different kinases (Src, Clik, protein kinase C). [25] [26] [27] Muscle-specific PDLIM proteins are associated with Z-disc structures via α-actinin, and their loss leads to cardiac and skeletal myopathies in mice. 28, 29 In Drosophila cell lines, loss of PDLIM function disrupts integrin-mediated cell adhesion, thereby inducing abnormal cell shape and spreading in vitro, confirming similar phenotypes observed in mammalian cells. 30 CLP36 (Elfin, PDLIM1) is an adaptor protein that contains 1 PDZ domain at the N-terminus, a short linker region, and 1 LIM domain at the C-terminus. The knockdown of CLP36 in a trophoblast-derived choriocarcinoma cell line (BeWo) led to impaired formation of stress fibers and focal adhesions, resulting in the loss of cell morphology. 31 In human platelets, the PDZ domain of CLP36 has been shown to build a bridge between stress fibers and α-actinin-1 and to link plasma membrane Ca 2+ ATPase 4b to the actin cytoskeleton. 24, 32 However, as a result of the lack of genetic models, the in vivo function of CLP36 has not been studied to date.
Here, we show that CLP36 is the only PDLIM family member expressed in platelets. To study its function in platelet physiology, we generated 2 mutant mouse lines: Clp36 ΔLIM expressing low amounts of a truncated chimeric form of CLP36 and Clp36 −/− mice lacking the entire protein. Although platelets from both mouse lines showed unaltered actin turnover, the lack of functional CLP36 resulted in marked hyperactivity of the GPVI-ITAM signaling pathway and a prothrombotic phenotype.
Methods
Detailed Methods are provided in the Online Supplement.
Results

Generation of Clp36 ΔLIM Mice
The partially overlapping expression profiles of PDLIMs in different mouse tissues and the similar domain structure of actinin-associated LIM protein, reversion-induced LIM protein, and CLP36 22 indicated that the biological function of these proteins may be redundant in vivo. To assess the expression of members of the PDLIM family in platelets, reverse-transcriptase polymerase chain reaction was performed. Interestingly, we found only CLP36 mRNA but no other PDLIM mRNAs were expressed in platelets ( Figure 1A) . The unique expression of CLP36 in platelets suggested that disruption of CLP36 function cannot be compensated by other PDLIM proteins. Immunofluorescence confocal microscopy of wild-type (Wt) platelets spread on fibrinogen showed that CLP36 is highly expressed with dotted appearance throughout the platelet cytoskeleton, except for the central granule body ( Figure 1B) .
To study the physiological function of CLP36 in vivo, we generated mice in which the Clp36 gene was disrupted by insertion of an intronic geomycin (Geo) gene-trap cassette into intron 5 located upstream of exons encoding the LIM domain (Online Figure IA) . Insertion of the Geo cassette resulted in expression of a chimeric CLP36 ΔLIM -β-GEO fusion protein. Immunoblotting with an antibody recognizing the PDZ domain (ab64971) of CLP36 detected the CLP36 ΔLIM -β-GEO protein at the expected size of ≈130 kDa, but at very low levels in comparison with the Wt protein (Online Figure  IB) . The absence of the C-terminal LIM domain was verified using another antibody (ab17022; Online Figure IB ). The mice homozygously expressing this low amount of the CLP36 ΔLIM -β-GEO protein are referred to as Clp36 ΔLIM mice. Clp36 ΔLIM mice were born following the Mendelian distribution and developed normally. Histological analysis of different hematopoietic organs of Clp36 ΔLIM mice revealed no obvious hematological diseases or other alterations until the age of 12 months (data not shown). Transmission electron microscopy and determination of the mean platelet volume of resting platelets revealed a slightly increased size of the mutant platelets compared with Wt platelets ( Figure 1C ). However, blood platelet counts and surface expression of major surface receptors, such as GPIb-V-IX, GPVI, and β1 and β3 integrins, were normal, except for a slight elevation of CD9 expression (Online Table I ). The life span of Clp36 ΔLIM platelets also was similar to that of Wt platelets ( Figure 1D ). Together, these results demonstrated that the LIM domain of CLP36 is dispensable for megakaryopoiesis and platelet production. To study the role of CLP36 in actin rearrangements, Wt and Clp36 ΔLIM platelets were allowed to spread on fibrinogen-coated coverslips in the presence of thrombin (0.01 U/mL). Wt and Clp36 ΔLIM platelets spread with similar kinetics, and after 20 minutes the number of fully spread platelets also was comparable between the 2 groups (Online Figure IC ). In addition, F-actin assembly (Online Figure  ID) was similar between Wt and mutant platelets, and their cytoskeleton (actin and tubulin) appeared indistinguishable during activation and spreading (Online Figure IIA) . 
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Enhanced GPVI Signaling in Clp36 ΔLIM Platelets
To assess the function of CLP36 in platelet activation, flow cytometric analysis of integrin αIIbβ3 activation using the JON/A-PE antibody 33 and P-selectin surface exposure as a marker of α-granule release was performed with Wt and Clp36 ΔLIM platelets. In this experimental setting, highly diluted platelet suspensions were used, which largely excluded the accumulation of released secondary mediators.
Activation of Clp36 ΔLIM platelets was normal in response to the G-protein-coupled receptor agonists ADP, thrombin, and the stable thromboxane A2 analog U46619 (Figure 2A ). In contrast, the response of Clp36 ΔLIM platelets to GPVI agonists (collagen-related peptide [CRP], convulxin) was markedly increased, and this effect was most evident at low agonist concentrations ( Figure 2B ). Of note, no significant differences on agonist-induced activation were observed between Wt mice and mice heterozygous for the mutation (Clp36 +/ΔLIM ; Online Figure IIB ). To study the functional consequences of increased αIIbβ3 integrin activation and degranulation in Clp36 ΔLIM platelets, aggregation responses to different agonists were assessed. Clp36 ΔLIM platelets aggregated normally in response to G-proteincoupled receptor agonists (thrombin, ADP, U46619) at all tested concentrations ( Figure 3A , left). In contrast, on stimulation with GPVI agonists (CRP, collagen, convulxin), a markedly enhanced aggregation response was observed in Clp36 ΔLIM platelets. This effect was most detectable at threshold concentrations of these agonists that did not induce aggregation of Wt platelets ( Figure 3A , right). In contrast, at higher concentrations of GPVI agonists, no significant difference in aggregation was detected between Wt and mutant platelets. Notably, Clp36 ΔLIM platelets did not aggregate spontaneously or on stimulation with epinephrine (data not shown), indicating that they were not in a preactivated state per se. The enhanced GPVI-induced aggregation response also was associated with enhanced dense granule secretion as shown by faster and increased ATP release in response to low concentrations of collagen or CRP. In contrast, no differences in ATP release between Wt and Clp36 ΔLIM platelets were detectable in response to thrombin (data not shown) or at high concentrations of GPVI agonists ( Figure 3B ).
Increased GPVI-Induced Tyrosine Phosphorylation, Inositol-1,4,5-Trisphosphate Production, and Ca 2+ Mobilization in Clp36 ΔLIM Platelets
Agonist-induced platelet activation and aggregation require an increase in [Ca 2+ ] i that occurs through release of Ca 2+ from intracellular stores, followed by Ca 2+ entry through the plasma membrane Ca 2+ channels. 34 To test whether the observed GPVI-ITAM-induced activation response of Clp36 ΔLIM platelets was based on altered Ca 2+ signaling, we studied agonist-induced changes in [Ca 2+ ] i fluorometrically. Store release in the absence of extracellular Ca 2+ in response to CRP was significantly elevated in Clp36 ΔLIM platelets compared with Wt controls (CRP 1 µg/mL; Wt: 30±12 nmol/L vs Clp36 ΔLIM : 60±10 nmol/L; P<0.05; Figure 4A and Online Figure IIC ). As a result, the subsequent Ca 2+ influx also was markedly increased in the presence of extracellular Ca 2+ in Clp36 ΔLIM platelets (CRP 1 µg/mL; Wt: 180±20 nmol/L vs Clp36 ΔLIM : 380±35 nmol/L; P<0.01; Figure 4B and Online Figure IIC , bottom) In contrast, no differences were observed in Ca 2+ store release or Ca 2+ influx in response to thrombin or ADP ( Figure 4A and 4B). To further assess the mechanism underlying the hyperreactivity of Clp36 ΔLIM platelets to GPVI stimulation, changes in tyrosine phosphorylation patterns were analyzed. At low concentrations of CRP (0.1 µg/mL), Wt platelets displayed only a small increase in tyrosine phosphorylation, whereas a marked increase in tyrosine phosphorylation of numerous platelet proteins, including those comigrating with PLCγ2, Fyn, Lyn, and the FcRγ chain, was observed in Clp36 ΔLIM platelets ( Figure 5A ). At high concentrations of CRP (5 µg/mL), the increases in tyrosine phosphorylation were similar in Wt and mutant platelets (data not shown). To confirm that the enhanced phosphorylation of signaling molecules in Clp36 ΔLIM platelets resulted in an increased PLCγ2 activity, we measured the amount of inositol-1,4,5trisphosphate indirectly using an inositol monophosphate ELISA. 35 Although inositol monophosphate production in response to thrombin was similar in Wt and Clp36 ΔLIM platelets (1551±307 nmol/L [Wt] vs 1742±186 nmol/L (Clp36 ΔLIM ); P=0.42), the response to CRP at both tested concentrations was markedly elevated in Clp36 ΔLIM platelets compared with Wt, suggesting enhanced activity of PLCγ2 in the mutant platelets (427±45 nmol/L [Wt] vs 842±197 nmol/L (Clp36 ΔLIM ); P<0.001 for CRP 1 µg/mL and Wt: 311±99 nmol/L vs Clp36 ΔLIM : 1049±493 nmol/L; P<0.01 for CRP 0.1 µg/mL; Figure 5B and Online Figure 2D ). Taken together, these results suggested that CLP36 acts as a negative regulator of GPVI signaling.
Enhanced Aggregate Formation and Procoagulant Activity of Clp36 ΔLIM Platelets on Collagen Under Flow
To study the consequences of enhanced GPVI signaling in Clp36 ΔLIM platelets for thrombus formation under flow, anticoagulated whole blood was perfused over collagen at different shear rates. At high shear rates (1700 s −1 ), no significant differences in surface coverage were observed between the 2 groups, but increased thrombus volumes were found for Clp36 ΔLIM platelets (Online Figure IIIA) . In contrast, at intermediate shear rates (1000 s −1 ), Clp36 ΔLIM platelets displayed both increased surface coverage and thrombus volumes ( Figure  6A ) compared with Wt controls (31.4±4% [Wt] vs 46.5±5% (Clp36 ΔLIM ); P<0.001). Interestingly, Clp36 ΔLIM and Wt platelets and Clp36 ΔLIM (gray) mice were stimulated with the indicated agonists for 5 minutes at 37°C. Platelets were lyzed, and IP 1 , a specific metabolite of inositol-1,4,5-trisphosphate (IP 3 ), was quantified using an ELISA assay. Results are given as the mean IP 1 concentration (nmol/L)±SD (n=4 per group). MW indicates molecular weight; Thr, thrombin. adhered to a similar extent when whole blood was perfused over fibrinogen-coated (60 µg/mL) coverslips at an intermediate shear rate of 1000 s −1 (Online Figure IIIB) . Activated αIIbβ3 integrin and increased Ca 2+ mobilization have been implicated in the coagulant activity of platelets. 36, 37 To determine the role of CLP36 in this process, anticoagulated whole blood from Wt or Clp36 ΔLIM mice was perfused over a collagen-coated surface at a shear rate of 1700 s −1 . Exposure of procoagulant phosphatidylserine was determined using Annexin V-Dylight-488 staining. The number of phosphatidylserine-positive platelets was significantly increased in Clp36 ΔLIM blood samples compared with Wt controls ( Figure  6B) . Thus, the enhanced GPVI-mediated activation responses resulted in an increased procoagulant activity of Clp36 ΔLIM platelets.
Accelerated Arterial Thrombus Formation but Normal Bleeding Times in Clp36 ΔLIM Mice
To assess the in vivo consequences of enhanced GPVI signaling in Clp36 ΔLIM platelets, thrombus growth was studied in a model of arterial thrombosis in which the abdominal aorta was mechanically injured and blood flow was monitored by an ultrasonic perivascular Doppler flowmeter. In this model, thrombus formation was triggered predominantly by collagen and thus occurred in a GPVI-ITAM-PLCγ2-dependent manner. 38 To rule out the possibility that deficiency of the LIM domain in cells of the vessel wall might influence thrombus formation and hemostatic function, mutation of the LIM domain was restricted to the hematopoietic system by transferring bone marrow cells from Clp36 ΔLIM donor mice into lethally irradiated Wt recipient mice and vice versa. Although irreversible occlusion of the aorta occurred with similar kinetics in Wt controls and Clp36 +/+ bone marrow chimeras (BMC) with mean time to occlusion for Wt control of 260±59 seconds and for Clp36 +/+ BMC of 350±131 seconds (P=0.07), occlusion times were markedly reduced in Clp36 ΔLIM BMC (132±56 s; P<0.001), reflecting faster occlusive thrombus formation ( Figure 6C ).
Tail bleeding times were measured to determine the hemostatic function of Clp36 ΔLIM platelets. No significant hemostatic defect was observed in Wt and Clp36 ΔLIM mice or in BMC mice transplanted with Clp36 +/+ or Clp36 ΔLIM cells (mean bleeding time: 47±22 s [Clp36 +/+ ] vs 57±54 s [Clp36 ΔLIM ]; P=0.48; Figure 6D ).
Enhanced GPVI Signaling in Clp36 −/− Mice
The expression of chimeric proteins even at extremely low levels might lead to aberrant signaling. To exclude the possibility that low amount of the CLP36 ΔLIM -β-GEO protein caused the observed hyperreactive GPVI/ITAM signaling in Clp36 ΔLIM platelets, we generated Clp36 −/− mice (Online Figure IA, bottom) . Clp36 −/− mice had normal platelet characteristics with platelet size, counts, and surface glycoprotein expression profile similar to Wt platelets (Online Table  II ). Strikingly, Clp36 −/− platelets, very similar to Clp36 ΔLIM platelets, displayed a pronounced hyperreactivity to GPVI agonists, as revealed by flow cytometric analysis of αIIbβ3 integrin activation and P-selectin exposure ( Figure 7A ) as well as aggregometry ( Figure 7B) , and again this effect was most evident at low agonist concentrations. In line with the data obtained with Clp36 ΔLIM platelets, Clp36 −/− platelets displayed unaltered activation responses to the G-protein-coupled receptor agonists ADP, thrombin, and U46619 ( Figure 7A and 7B ). Furthermore, when Clp36 −/− platelets were perfused over collagen at an intermediate shear rate (1000 s −1 ), they showed increased surface coverage (38.4±4.1% [Wt] vs 60.5±9.8% (Clp36 −/− ); P<0.001; Figure 7C ) and thrombus volumes at the end of the perfusion phase. Similar to Clp36 ΔLIM platelets, Clp36 −/− platelets also adhered and spread normally on fibrinogen (Online Figure  IIIC) , and their actin cytoskeleton also was unaltered (Online Figure IIID) . Importantly, the results obtained for Clp36 −/− platelets were similar to those obtained with Clp36 ΔLIM platelets, further suggesting that the Clp36 ΔLIM mutation results in a knockout-like phenotype, at least in platelets. Together, these results confirmed that CLP36 acts as a negative regulator of GPVI signaling also under flow.
CLP36 Interacts With Components of the GPVI Signalosome and Is Degraded During Platelet Activation
Based on the marked hyperreactivity of CLP36 mutant platelets to GPVI agonists, we speculated that CLP36 might interact with components of the GPVI signalosome. To test this directly, we performed coimmunopreciptation experiments. We were unable to detect a direct interaction between CLP36 and GPVI in the absence of chemical crosslinkers (data not shown). However, CLP36 could be coimmunoprecipitated with GPVI when platelets have been treated beforehand with the reducible crosslinker dimethyl 3,3´-dithiobispropionimidate 2 HCl ( Figure 8A ). We also detected an interaction between CLP36 and linker of activated T cells (LAT) in Wt platelets on chemical crosslinking. Apart from the weak interaction of CLP36 with GPVI and LAT, we identified strong binding of CLP36 to the calcium sensor protein STIM1 by mass spectrometric analysis of the platelet STIM1 complex (Online Figure  IVA and Online Table III ). This is an interesting observation because both the gain-of-function or loss-of-function mutations of Stim1 in platelets result not only in a defect in SOCE but also in a selective defect in the GPVI-ITAM signaling pathway 13, 14 that seems to be at least partially independent of its SOCE-regulating function. 13 Platelet activation is controlled by various mechanisms, including proteolytic degradation of intracellular proteins. Calpain, the major calcium-dependent protease in platelets, undergoes activation on increase in [Ca 2+ ] i . In vitro experiments in mouse muscle cells with calpain-3 knockout mice revealed that CLP36 was cleaved directly by the protease. 39 To study this process in platelets, we analyzed degradation of CLP36 on stimulation with the GPVI agonist convulxin and the Ca 2+ ionophore ionomycin in the absence or presence of the calpain inhibitor calpeptin. Although ionomycin induced the virtually complete loss of intact CLP36 within 10 minutes, a more delayed effect was seen with convulxin, which could be inhibited in the presence of calpeptin ( Figure 8B) . These results demonstrated that CLP36 is degraded in a calpain-dependent manner during platelet activation.
Discussion
In this study, we identified the PDLIM family protein CLP36 as a major regulator of GPVI-induced platelet activation. We demonstrate that the loss of CLP36 function results in markedly enhanced platelet activation in response to collagen in vitro and a prothrombotic phenotype in vivo. This finding was unexpected because PDLIM family members have, so far, not been associated with ITAM signaling in platelets or other cell types. In contrast, most of PDLIMs associate with stress fibers and with the focal adhesion complex via α-actinin. 21, 24, 40, 41 Stress fibers and focal adhesions were lost in knockout or knockdown cell lines of PDLIMs, and this induced altered cell morphology and spreading. 30 Therefore, PDLIMs were proposed to play a critical role in stress fiber formation 41 and integrin-mediated focal adhesion. 30, 31 Our reverse-transcriptase polymerase chain reaction studies revealed that CLP36 is the only PDLIM family member expressed in platelets ( Figure 1A) , making these cells a good model to study its function.
The targeting strategy used to generate Clp36 ΔLIM mice did not ablate CLP36 expression but resulted in the expression of a truncated CLP36 protein fused with β-GEO protein at very low levels. Clp36 ΔLIM platelets displayed normal spreading and stress fiber formation on fibrinogen (Online Figure IC  and ID) . Interestingly, the subcellular localization of the CLP36 ΔLIM protein in spread platelets was similar to the Wt protein in control platelets (Online Figure IVB) . This might be attributed to the intact N-terminal PDZ domain of the chimeric CLP36 protein, which still could associate with the actin cytoskeleton. The interaction of CLP36 with α-actinin, however, was not essential for actin turnover in platelets because Clp36 −/− platelets were able to form filopodia and lamellipodia, and, finally, were able to spread with similar kinetics as Wt platelets (Online Figure IIIC and IIID) . Together, these data demonstrate that CLP36 is dispensable for actin rearrangements in platelets.
The enhanced integrin αIIbβ3 activation and granule secretion of Clp36 ∆LIM and Clp36 −/− platelets (Figures 2 and 7) in response to GPVI agonists were associated with an increased PLCγ2 activity ( Figure 5 ) caused by abnormal function of downstream signaling molecules of GPVI that are not required for G-protein-coupled receptor signaling. In both mutant mouse lines, this defect resulted in enhanced aggregation and an increased ability of the platelets to form aggregates on collagen under flow conditions ( Figures 6A and 7C ). This strongly suggests that Clp36 ΔLIM platelets display a CLP36 knockoutlike phenotype and that the low amounts of CLP36 ΔLIM -β-GEO protein have no detectable effect on GPVI-ITAM signaling or actin rearrangements. Surface expression of GPVI in Clp36 ∆LIM and Clp36 −/− platelets was unaltered compared with Wt controls (Online Tables I and II) , thus excluding the possibility of enhanced signaling as a result of higher receptor numbers on the platelet surface.
Several proteins have been identified by knockout approaches to negatively regulate GPVI-ITAM-PLCγ2 signaling, including platelet endothelial cell adhesion molecule, 15 TULA-2, 17 and carcinoembryonic antigen cell adhesion molecule-1. 16 Mice lacking these proteins, similar to Clp36 ∆LIM and Clp36 −/− mice, display platelet hyperreactivity toward GPVI agonists in vitro and a prothombotic phenotype in vivo, demonstrating the (patho)physiological importance of the negative feedback loop that controls GPVI signaling in platelets. Previous studies have shown that PDLIMs act as adapters between kinases and the actin cytoskeleton. [23] [24] [25] [26] [27] This is based on the observation that the PDZ domain of PDLIMs associates, in some cases, with the actin cytoskeleton via α-actinin or βtropomyosin and, in some cases, with different kinases via their LIM domains. The exact mechanism how CLP36 is associated with the negative feedback loop of GPVI could not be completely elucidated here, but our results indicate a complex mechanism that involves weak interactions of CLP36 with components of the GPVI signalosome ( Figure 8A ). Studies by Bertipaglia et al 39 revealed calpain-mediated cleavage of CLP36 in muscle cells. Interestingly, we also observed the loss of intact CLP36 on GPVI-induced platelet activation, which was blocked by the calpain inhibitor calpeptin ( Figure  8B ). Together, these results support a model in which CLP36 might serve as a brake to prevent unwanted platelet activation through GPVI in the intact vascular system. After an initial stimulus that triggers increases in [Ca 2+ ] i , calpain is activated and degrades CLP36, thereby releasing the brake of GPVI signaling and thus allowing full platelet activation. However, CLP36 may additionally contribute to the control of GPVI-ITAM signaling by other mechanisms. We identified CLP36 along with α-actinin and β-tropomyosin isoforms as interaction partners of the calcium sensor STIM1 during the mass spectrometric analysis of STIM1-Co-IP samples (Online Table III ). STIM1 deficiency virtually abolishes SOCE in platelets, 14 whereas a gain-of-function mutation of STIM1 (Stim1 Sax ) leads to enhanced SOCE. 13 Interestingly, however, both mutations result in defective GPVI-mediated signaling, indicating that lack or aberrant localization of STIM1 affects the GPVI-ITAM pathway independently of its role in Ca 2+ signaling. Based on this assumption, we speculate that CLP36 might negatively regulate the association of STIM1 with the GPVI signalosome in resting platelets, but further studies will be required to dissect the molecular interplay of the GPVI signalosome with STIM1 and CLP36.
Our studies with Clp36 −/− platelets revealed a similar hyperactivity of GPVI signaling as in Clp36 ∆LIM platelets, indicating that this effect is not based on an unphysiological activity of the chimeric CLP36 protein (Figure 7 and data not shown). Previously, CLP36 was proposed to be involved in the regulation of Ca 2+ homeostasis in human platelets. 32 It was shown that the PDZ domain of CLP36 interacts with plasma membrane Ca 2+ -ATPase, and the authors speculated that this association might regulate late events in platelet activation, such as clot retraction and stability. However, we found no impairment of clot retraction in Clp36 ∆LIM or Clp36 −/− platelets (Online Figure IVC) , demonstrating that CLP36 is dispensable for this process. The increased inositol-1,4,5trisphosphate production observed in Clp36 ΔLIM platelets on GPVI activation ( Figure 5B ) led to a faster and enhanced Ca 2+ release ( Figure 4A ) from the intracellular stores, which subsequently increased SOCE. 42 Notably, passive store depletion with thapsigargin did not lead to any differences in the kinetics of store release or SOCE between Wt and Clp36 ΔLIM platelets (Online Figure IVD) . Therefore, we conclude that CLP36 has no direct effect on the regulation of Ca 2+ store depletion or on the assembly and activation of the store-operated Ca 2+ complex. Apart from SOCE, platelets express ligand-gated channels such as transient receptor potential cation channel and P2X 1. 34 Transient receptor potential cation channel 6 has been identified as the major diacylglycerol-induced receptoroperated calcium channel in these cells. 43, 44 Enhanced phosphatidylinositol 4,5-bisphosphate hydrolysis by PLCγ2 in platelets lacking functional CPL36 may lead to increased cytoplasmic diacylglycerol levels, thereby potentially accelerating transient receptor potential cation channel 6-mediated Ca 2+ influx.
The function of CLP36 identified here as an inhibitor of GPVI-ITAM signaling is highly relevant in vivo because lack of functional CLP36 in the hematopoietic compartment resulted in accelerated occlusive thrombus formation in BMC mice in an arterial injury model. In contrast, tail bleeding times were unaltered in the mutant animals as well as in the chimeras, suggesting that the negative regulation of GPVI signaling may be particularly important to prevent intravascular occlusive thrombus formation. Based on this assumption, one may speculate that altered expression or activity of CLP36 in platelets might have an impact on the risk of acute ischemic diseases, such as myocardial infarction.
Taken together, we have shown that loss of the CLP36 LIM domain in platelets leads to increased PLCγ2 activity downstream of GPVI and thereby accelerates Ca 2+ store release and Ca 2+ influx, which in turn induces faster α-granule and dense granule secretion and integrin activation. These findings establish CLP36 as an important regulator of platelet activation and might provide a basis for the development of novel strategies to control intravascular platelet activation. 
